Jan 11, 2023 / 07:00PM GMT
Seth Schwartz -
Good morning, everyone. My name is Seth Schwartz, and I lead JPMorgan's health care investment banking practice in Australia. Great honor and privilege this morning to welcome and introduce Chris Behrenbruch, CEO and Managing Director of Telix Pharmaceuticals.
Christian P. Behrenbruch - Telix Pharmaceuticals Limited - Co-Founder, Group MD, CEO & Executive Director
Thanks very much, Seth, and it's a pleasure to be here to tell you about our very exciting company. I'm just going to get the slides up here.
Great. So just skipping over the customary disclaimer. So just a bit of a high-level overview of Telix, so we're a therapeutics company but with a strong precision medicine or theranostics bent. We have a commercial stage portfolio in diagnostic imaging. And particularly, we just launched our first product in prostate cancer, and I'm going to be talking a little bit more about that. We also just had a readout, a very nice strong readout on our Phase III trial in renal cancer. And so those are our 2 sort of commercial stage assets.
Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers